|
Feb. 09, 2023 |
|
|
Oct. 28, 2024 |
|
|
jRCT2031220627 |
A Single Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-2214 in Healthy Japanese Participants |
|
Single Dose Study of MK-2214 in Healthy Japanese Participants |
Tanaka Yoshiyuki |
||
MSD K.K. |
||
KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan |
||
+81-3-6272-1957 |
||
msdjrct@msd.com |
||
MSDJRCT inquiry mailbox |
||
MSD K.K. |
||
KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan |
||
+81-3-6272-1957 |
||
msdjrct@msd.com |
Complete |
Mar. 17, 2023 |
||
| Mar. 17, 2023 | ||
| 48 | ||
Interventional |
||
randomized controlled trial |
||
double blind |
||
placebo control |
||
parallel assignment |
||
other |
||
Healthy male or female aged 18 to 75 years old with BMI 18 to 30 kg/m2 |
||
Has a history of clinically significant abnormalities or diseases |
||
| 18age old over | ||
| 75age old under | ||
Both |
||
Alzheimer's Disease |
||
Single i.v. dosing |
||
Adverse event |
||
AUC0-inf, AUC0-last, AUC0-140d, AUC0-28d, Cmax, Tmax, t1/2, CL and Vz |
||
| MSD K.K. |
| P-One Clinic, Keikokai Medical Corp. Institutional Review Board | |
| View Tower Hachioji 4F, 8-1, Yokamachi, Hachioji-shi, Tokyo | |
+81-42-625-5216 |
|
| irbjimukyoku@keikokai-gr.or.jp | |
| Approval | |
Feb. 27, 2023 |
Yes |
|
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf |
| なし |
none |